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Abstract 
Human cytomegalovirus (HCMV) is a highly species-specific, common human pathogen.  While 
a large majority of people are infected with HCMV worldwide, infection is typically 
asymptomatic in immune competent individuals.  To enhance virus persistence and avoid 
immune detection by the host, HCMV exploits the strategy of encoding homologs of cellular 
cytokines.  One factor produced by HCMV-infected cells is the viral cytokine cmvIL-10, which 
acts through the cellular IL-10 receptor to induce downstream cell signaling.  In instances where 
HCMV-infected cells infiltrate the tumor microenvironment, the presence of cmvIL-10 in may 
initiate events that promote a more invasive tumor phenotype.   Cancer cells that express fewer 
adhesion molecules, which allow cells to break off from the primary tumor, are more likely to 
metastasize.  In addition, matrix metalloproteinases (MMPs) degrade the extracellular matrix, an 
effect which promotes cancer cell dissemination by permitting tumor cells access to the vascular 
and lymphatic systems.  We found that MCF-7 human breast cancer cells express the cellular IL-
10 receptor and that treatment with cmvIL-10 results in changes in gene expression and cellular 
activity related to cancer progression.   We demonstrate that cmvIL-10 alters expression of cell 
adhesion molecules and increases MMP gene expression.   Breast cancer cells also exhibit more 
robust migration in the presence of cmvIL-10.   CmvIL-10 may cooperate with other factors 
secreted by HCMV infected cells, and the secretome of HCMV infected fibroblasts are 
characterized.  The results indicate that breast cancer cells exposed to cmvIL-10 undergo 
changes that could lead to the formation of more invasive tumors.   This observation suggests 
that HCMV-positive cancer patients may have the potential to develop more metastases and 
could benefit from the inclusion of anti-viral therapeutics in their treatment regimen. 
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Introduction 
Human cytomegalovirus (HCMV) is a highly species-specific, common human pathogen 
infecting people worldwide.  Seroprevalence of infection in the United States ranges from 50-
90% for middle aged adults (65, 78) and correlates directly to exchange of bodily fluids (18).  
Factors elevating HCMV incidence between populations include poor socioeconomic conditions 
and high-risk sexual practices (14, 18, 49).  Seroprevalence may be greater than 95% in 
developing countries (65).   
While a large majority of people are eventually infected with HCMV, infection is typically 
asymptomatic in healthy individuals.  However, in immunocompromised hosts such as transplant 
recipients and HIV patients, HCMV can produce serious illness or fatal conditions (14, 71).  
Additionally, the developing fetus is threatened when a pregnant woman experiences primary 
exposure to HCMV.  Congenital cytomegalovirus infection is the leading infectious cause of 
mental retardation and sensorineural hearing loss in the United States, affecting about 8,000 
American children per year (8).  Furthermore, while infection in the immunocompetent host is 
generally asymptomatic,  HCMV actively modulates multiple cell regulatory and signaling 
pathways in healthy HCMV seropositive humans (9).  Such manipulations of cellular pathways 
result in extensive micro-effects in the host organism, such as modification of the cell cycle and 
regulation of the immune system.  These pervasive health concerns illustrate compelling reasons 
for continued investigation of the biology and immunology of HCMV. 
HCMV belongs to the β subgroup of the Herpesviridae family and, like other herpesviruses, 
establishes lifelong latency in the host.  HCMV contains a large double-stranded, linear DNA 
genome of 235kb in length.  HCMV DNA is composed of two unique components denoted 
Unique Long (UL) and Unique Short (US), which are each flanked by direct and inverted repeat 
elements (Figure 1) (35).  The chromosome is able to isomerize at the junction of the two 
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Figure 1. A schematic map of the HCMV genome.  The HCMV genome is organized as 
two unique sequences (UL) and (US) flanked by two sets of repeat elements, TR and IR, long(L) 
and short(S).  Figure adapted from Kotenko et. al., 2000 (35). 
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segments to create four possible different genomic isomers (46), each of which encode for 165  
HCMV genes (17).  The DNA core is enclosed in a 100 nm diameter icosahedral capsid and 
surrounded by a tegument of phosophoproteins.  These components are enveloped by a lipid 
bilayer carrying an abundance of viral glycoproteins.  The entire virus particle ranges in size 
from 150-200 nm (46). 
HCMV infects many human cell types in vivo, including epithelial cells, fibroblasts, 
monocytes, macrophages, and lymphocytes.  In cell culture, however, HCMV exhibits a highly 
restrictive host range, preferring primary differentiated skin or lung fibroblasts (46).  The cellular 
determinants of HCMV tropism and attachment are numerous, and many have still not been 
completely identified (15, 45).  Basically, HCMV binds to cell surfaces by the interaction of 
virion envelope proteins, often glycoprotein B (gB), with heparan sulfate proteoglycans (16), 
which concentrates virions on cell surfaces to promote other interactions with cellular receptors 
(5). 
HCMV entry into the cell is not straightforward or uniformly agreed upon by researchers.  
The cellular receptors utilized for viral entry, particularly Platelet Devived Growth Factor 
Receptor α (PDGFRα), are debated (61, 72).  It is widely hypothesized that the envelope 
glycoproteins which HCMV employs to gain entry vary according to cell type being infected 
(28).  Entry of HCMV into all human cell types involves at least viral envelope glycoprotein H 
(gH) and glycoprotein L (gL).  For infection of epithelial and endothelial cells, leukocytes, and 
monocytes, HCMV assembles a glycoprotein complex composed of gH/gL and three other 
virally encoded proteins: UL128, UL130, and UL131 (72).  The virion is then internalized by 
endocytosis followed by fusion with endosomal membranes (56).  In contrast, this five 
glycoprotein complex is not required for viral entry into human fibroblasts.  Here the viral 
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envelope, assisted by gH/gL and likely driven by the interaction of gB and integrins (26), fuses 
directly with the cellular plasma membrane and the viral capsid is deposited into the cytoplasm.  
These two different pathways of entry require distinct combinations of HCMV envelope 
glycoproteins.   
  The genome-carrying capsid is not the only organic material deposited into the cell upon 
virus entry.  The tegument layer is an area between the lipid envelope and the capsid in HCMV 
virions that harbors over 100 distinct virally-coded and cellular proteins (33).  These tegument 
proteins are dispensed into the cellular space and serve, in part, to mediate the delivery of the 
capsid along microtubules to the cell nucleus (33).  Additional tegument proteins migrate 
independently to the nucleus, while others remain in the cytoplasm.  Further tegument material 
includes mRNA ready for immediate translation by cellular ribosomes (6).  In this critical stage 
of infection when the virus will commit to active replication or latency, the proteins and mRNA 
from the tegument layer begin to establish active regulatory systems that determine the activity 
of the infected cell (25).  In this way, HCMV modulates the host cellular environment before the 
viral genome even arrives at the nucleus for transcription. 
HCMV genome replication is slow compared to other herpesviruses, confined by early and 
late stage gene expression.  Upon entry into the host nucleus, the viral tegument protein pp71 
commits the virus to the lytic cycle by performing as a transactivator in the nucleus, promoting 
activation of the strong Major Immediate Early Promoter/enhancer (MIEP) (33).  MIEP is 
upstream of the major IE locus (ie1/ie2) containing genes encoding α (Immediate early) gene 
products.  MIEP is a very strong enhancer region employing a plethora of binding sites for 
cellular transcription factors and viral proteins (46).  Host cell RNA polymerase II recognizes 
viral gene promoters and transcribes the nuclear phosphoprotein gene products IE1 and IE2.  
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These proteins are involved in both positive and negative regulation of viral gene expression.  
HCMV IE1 autostimulates its own synthesis through activation of MIEP and modulation of the 
cellular environment, further encouraging MIEP (15).  HCMV IE2 shuts off ie1/ie2 and 
transitions viral expression from α to β (delayed early) gene expression.  HCMV DNA 
polymerase, as well as origin binding proteins and other viral replication proteins, are translated 
by cellular ribosomes and transported to the nucleus during early gene expression as cellular 
metabolism is stimulated (46).   Viral DNA replication begins at the oriLyt replication origin.  γ 
(Late) gene expression ensues 24-36 hours after infection, encoding for structural proteins and 
proteins enabling progeny virus assembly (46).  Maximum HCMV replication occurs 72-96 
hours post-infection, and may persist for one week (25).   
Overall, lytic cycle HCMV infection (Figure 2) results in viral gene expression and 
replication and is contingent upon cell vitality and activity.  Unlike other herpesviruses, HCMV 
DNA proliferation is dependent on cellular DNA replication, so virus replication is more rapid in 
active cells than resting cells.  Acute HCMV infection stimulates cellular nucleic acid processing 
and synthesis of gene products in order to create an optimum, active host for virus proliferation.  
The ability of HCMV to stimulate cellular metabolism enough to permit virus replication, yet 
avoid immune system clearance in an organism under strict surveillance is impressive.   
While stimulating cellular metabolism, the virus needs to avoid recognition in order to persist 
in its host.  This challenging dichotomy demonstrates a substantial evolutionary pressure to 
develop strategies to avoid detection and elimination by the human immune system.  First, 
HCMV prefers to replicate in tissues with less stringent immune surveillance, such as the 
epithelial cells of the salivary glands, which do not express a sufficient number of major 
histocompatibility complex (MHC) class I molecules to coordinate a complete immune response   
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Figure 2. A schematic map of the HCMV lytic cycle.  1. Cellular transcriptional factors 
are activated.  2. Viral mRNA is translated.  Viral DNA is transported to the nucleus.  3. 
Activated transcriptional factors encourage viral and cellular DNA expression in the nucleus.  
Viral DNA is replicated.  4. Viral DNA, viral and cellular proteins and virion transcripts are 
packaged.  Infectious virus is released.  Figure adapted from Huang, et al., 2000 (25). 
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(24).  For this reason HCMV was once known as “salivary gland virus,” and was first isolated 
from greatly enlarged cells, or cytomegalic inclusion bodies, of the salivary glands (63).  Newly 
assembled viruses are seamlessly transmitted to new hosts in saliva, permitting dissemination.  
HCMV does not, however, merely hide in salivary glands to avoid immune detection by the host, 
but actively orchestrates its evasion from immune clearance.  As mentioned, HCMV is capable 
of infecting a broad array of cell types and, like other herpesviruses, HCMV establishes latent 
infection at some point following primary productive infection (59). 
Latent infection is the absence of detectable virus despite the presence of viral DNA; HCMV 
commences a life-long co-existence with the host.  Latent HCMV is believed to reside primarily 
in myeloid progenitor cells in the bone marrow (58), but not all sites for latency are documented.   
Latency involves strategies to allow viral persistence through tactics of evasion from immune 
system clearance, despite an enormous anti-HCMV response by CD4+ and CD8+ T cells (40).   
Cells of the human immune system rely on a system of secreted proteins including cytokines, 
chemokines, and their receptors to interact with each other and coordinate an effective immune 
response.  Cytokines are proteins secreted by cells to convey information to other cells.  Cells 
that have the appropriate receptor for the cytokine are capable of receiving the message and 
transmitting the signal inside the cell via intramolecular pathways (63).  Chemokines, or 
chemotactic cytokines, are a subtype of cytokine that attract immune cells by inducing migration 
to sites of infection or damage.  In infected cells, HCMV can produce over 250 proteins, but only 
about 50-60 are essential for viral replication (60). Thus, the vast majority of viral proteins 
enable the virus to persist with the host.  HCMV has hijacked the cellular language of cytokines 
and chemokines by developing numerous homologs of cellular cytokines and cytokine receptors 
as a strategy to limit immune control, a phenomenon known as molecular mimicry.  The latent 
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infection launched by HCMV involves the production and secretion of these immunomodulatory 
homologs to restrict the cell cycle, evade apoptosis and diminish immune recognition and 
response (63).  These proteins act through highly sophisticated mechanisms to control, silence, 
and counteract normal immune mechanisms in order to facilitate viral production and to avoid 
detection and elimination of the virus.   
One factor expressed by HCMV to manipulate the host environment is HCMV interleukin-10 
(cmvIL-10).  CmvIL-10 is a homolog of human IL-10, a cellular cytokine primarily involved in 
immune suppression.  Human IL-10 has effects on many cell types, but predominantly regulates 
the immune response by targeting monocytes to inhibit production of cytokines, including IL-1α, 
IL-1β, IL-6, and TNFα (63).  A reduction of these cytokines limits the inflammatory response, 
counteracting activity mediated by interferon gamma (IFNγ).  Additionally, human IL-10 down-
regulates MHC class II and co-stimulatory molecules (19, 64) to decrease T-cell effector activity.  
The HCMV mimic of this cytokine, cmvIL-10, retains these same powerful abilities.  
CmvIL-10 is encoded by the viral gene UL111A (Figure 3).  During productive infection, the 
175 amino acid protein is produced from splicing of the three exons and two introns of gene 
UL111A with late kinetics (35, 37).  CmvIL-10 has 27% amino acid identity to human IL-10 yet 
binds to the cellular IL-10 receptor (IL-10R) with greater affinity than human IL-10 itself (32).  
Alternative splicing of the UL111A gene produces a smaller 139 amino acid protein denoted 
LAcmvIL-10 that is expressed with early kinetics in productive infection and continues to be 
expressed during latent infection (30, 31).  For the purpose of this investigation, discussions of 
cmvIL-10 will focus on the larger, full-size version of the two transcripts.  CmvIL-10 binds to 
cellular receptor IL-10R, activating the JAK/STAT3 pathway (Figure 4) (62).  Initially, cmvIL-
10 interacts with the extracellular domain of ligand binding subunit IL-10Rα, which is supported 
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Figure 3. A schematic map of the gene encoding for cmvIL-10.  The 175 amino acid 
cmvIL-10 protein is encoded by three exons from the viral gene UL111A (ORF 79).  Figure 
from Kotenko et. al., 2000 (35). 
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Figure 4. A schematic illustration of Stat3 activation by cmvIL-10.  The binding of 
cmvIL-10 to the receptor results in phosphorylation of Jak1.  Stat3 is recruited to the 
phosphorylated receptor and also phosphorylated.  Stat3 dimerizes and migrates into the nucleus, 
where it binds to the promoter of target genes, stimulating expression.
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by signaling subunit IL-10Rβ.  The interaction engages the tyrosine kinases Jak1 and Tyk2 that 
are constitutively associated with the intracellular portions of the receptor.  Phosphorylated Jak1 
and Tyk2 cross-phosphorylate the intracellular chain of IL-10Rα.  STAT3 (signal transducer and 
activator of transcription-3) docks to these phosphorylated tyrosine residues, binds via its SH2 
domain, and is phosphorylated.  STAT3 homodimerizes, dissociates from the receptor, and 
translocates to the nucleus to bind to promoters and induce transcription (20).    The resulting 
effects include inhibition of cytokine synthesis and downregulation of MHC class II molecules, 
resulting in a reduction in proliferation and differentiation of peripheral blood mononuclear cells 
of the immune system (31, 59, 64).  In this way, cmvIL-10 promotes transcription of human IL-
10-associated genes via STAT3 activation. 
When cmvIL-10 is secreted from infected cells, the resulting suppressive effects are capable 
of affecting neighboring uninfected cells in a paracrine fashion (47, 64).  HCMV can employ the 
properties of cmvIL-10 to manipulate the host cell and surrounding uninfected tissue to silence 
signaling mechanisms, resulting in a failure to attract local immune cells to the site of infection.  
The dampening of host defense mechanisms through the expression of cmvIL-10 establishes a 
more preferable environment for the virus.  However, the potent immunosuppressive activities of 
cmvIL-10 may have vast implications for the immunocompetent host in circumstances where 
cancerous cells are in the vicinity of HCMV infected cells.  Specifically, research is emerging to 
suggest that the immunomodulatory proteins encoded by HCMV may also contribute to the 
promotion of common inflammation-related diseases, such as cancer (60).  The term 
oncomodulation indicates that while HCMV is not regarded as an oncogenic virus, HCMV 
infection may promote malignancy of tumor cells.  Current research suggests there is a 
connection between HCMV and cancer progression (11-13, 40-43) (Figure 5). 
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Figure 5. HCMV may infect tumor and stromal cells, resulting in increased tumor 
malignancy.  The interaction between HCMV-infected or non-infected cell types may be crucial 
for oncomodulatory effects.  Figure adapted from Michaelis et. al., 2011 (41). 
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Furthermore, cancer involves a genetic mutation in a cell that leads to uncontrolled 
proliferation, which could be exacerbated by the virally-altered immunoenvironment (10).  
Expression of HCMV gene products in or around an established tumor may accelerate 
progression of the tumor by promoting various signaling pathways critical to tumor growth such 
as mitogenesis, apoptosis, inflammation, angiogenesis, invasion and migration (11, 42).  The 
present research investigates the effects of viral cytokine cmvIL-10 on breast cancer cell 
metastasis. 
Metastatic breast cancer presents a colossal issue for women’s health.  In the United States, 
there are over 200,000 new diagnoses of invasive breast cancer annually. Nearly 40,000 
American women died of breast cancer in 2012 (1).  Diverse genetic mutations are responsible 
for the development of breast tumors, and there currently exist four molecular subtypes of breast 
cancer (70).  Subtype Luminal A consists of tumors expressing estrogen receptors (ER) on the 
surface but not human epidermal growth factor receptor-2 (HER2).  Subtype Luminal B includes 
tumors with estrogen receptors and HER2 on the cell surface.  Triple-Negative Subtype tumors 
have little or no estrogen receptors or HER2.  HER2 Subtype tumors have little or no estrogen 
receptors but are HER2 positive (70).  Table 1 provides the four breast cancer molecular 
subtypes and corresponding prevalence.   
Metastatic breast cancer is an advanced stage of breast cancer where a cancerous cell or 
group of cells has uprooted from the primary tumor in the breast and established a secondary 
tumor in another organ or part of the body (Figure 6).  Between one-half and two-thirds of 
American women diagnosed with Stage II and III breast cancer will develop at least one 
secondary tumor within 5 years of diagnosis (39).  Despite persistent screening efforts and 
preventative measures, one in eight women will develop metastatic breast cancer in their lifetime  
Bishop,	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Table 1. Molecular subtypes of breast cancer tumors.   
Subtype  These tumors tend to be  Prevalence (approximate)  
Luminal A ER+ and/or PR+, HER2-, low Ki67 40% 
Luminal B ER
+ and/or PR+, HER2+ (or HER2- with high 
Ki67) 20% 
Triple negative/basal-
like 
ER-, PR-, HER2-, cytokeratin 5/6+ and/or 
HER1+  15-25% 
HER2 Subtype ER-, PR-, HER2+ 10-15% 
 
*Adapted from Susan G. Komen for the Cure (68). 
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Figure 6. Metalloproteinases play a significant role in the metastatic process.  MMPs 
are associated with steps in the metastatic cascade involving matrix degradation, invasion and 
local migration.  Figure adapted from Chambers et. al., 1997 (7). 
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and one in 36 women will die from the disease (1). The metastatic process begins with invasion, 
in which the cancer cell breaks through the basal lamina of the primary tissue.  The cell enters 
the lymph or adheres to a capillary wall.  Intravasation involves the cell invading the capillary or 
being deposited into blood from the lymph and joining the circulatory system.  The cancer cell is 
violently transported to another part of the body and a vast majority of cancer cells do not 
survive this journey.  Extravasation entails the cancer cell escaping from the blood vessel in the 
new region.  The cancer cell migrates locally and begins to establish residence by adapting and 
transitioning to conform to the surrounding tissue.  The cancer cell commences to proliferate and 
develops into a secondary tumor (75).  Breast cancer tumors metastasize most frequently to bone, 
lungs, lymph nodes, liver, and brain (50).   
Invasion is promoted by the presence of matrix metalloproteinases (MMPs), a family of 
proteolytic enzymes that degrade the extracellular matrix (ECM) (73).  MMPs permit malignant 
tumor cells access to the vascular and lymphatic systems, leading to cancer cell dissemination 
(Figure 6) (7).  Elevated levels of MMP-13 have been found to correlate with poor prognoses in 
breast cancer patients (77).  In addition, evidence implicates the role of MMP-2 and MMP-9 in 
breast cancer genesis and progression (21, 66).  MMPs are inhibited by tissue inhibitor of 
metalloproteinases (TIMPs), wedge-like proteins with a continuous ridge that slots into the 
active site of the MMPs to prevent catalytic activity (48).    Furthermore, transforming growth 
factor-β1 (TGF-β1) is a multifuctional cytokine that plays a critical role in cell proliferation, 
migration, and synthesis of ECM.  Reported mechanisms of TGF-β1 activation include cleavage 
by metalloproteinases (69). Metastatic cancer progression, driven by MMPs, is a serious threat to 
the treatment and survival of cancer patients (51). 
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Considering the prevalent cmvIL-10 activity in modulation of the host cell environment in 
HCMV-positive individuals, the possibility of cmvIL-10 contributing to cancer cell metastasis is 
reasonable and worthy of investigation.  Here we show that cmvIL-10 treated breast cancer cells 
demonstrate an altered gene expression profile involving decreased cell-to-cell adhesion 
molecules and increased MMP-7, MMP-9 and MMP-10 levels.  Furthermore, cmvIL-10 
increases MCF7 cell migration, compared to untreated breast cancer cells.  These results 
demonstrate an oncomodulatory effect of cmvIL-10 that may promote breast cancer metastasis.  
Thus, HCMV and the cytokine cmvIL-10 offer viable therapeutic targets for the prevention of 
breast cancer progression that could contribute to the decline of breast cancer mortality. 
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Materials and Methods 
Cells.   MCF-7 (American Type Culture Collection, ATCC, Manassas, VA), an estrogen 
receptor-positive invasive ductal carcinoma breast cell line, was grown at 37°C in a humidified 
5% carbon dioxide incubator in Dulbecco’s Modified Eagle Medium Nutrient Mixture F12 
(DMEM/F12, GIBCO, Grand Island, NY) supplemented with 10% Fetal Bovine Serum (FBS, 
Sigma-Aldrich, St. Louis, MO).  HFF-1 (ATCC), normal human foreskin fibroblasts, were 
maintained at 37°C in a humidified 5% carbon dioxide incubator and grown in Dulbecco’s 
Modification of Eagle’s Medium (DMEM, Mediatech, Manassas, VA) supplemented with 15% 
FBS.  Cells were subcultured twice weekly by treatment with trypsin (Mediatech, Manassas, 
VA). 
Antibodies.  The antibodies used in flow cytometry analyses were goat anti-IL-10Rα (R&D 
Systems, Minneapolis, MN, FAB6280P) and mouse anti-IL10Rβ (R&D Systems, FAB874P).  
The antibodies used as isotypes for comparison were, respectively, goat IgG (R&D Systems, 
IC108P) and mouse IgG1 (R&D Systems, 554680).  For immunofluorescence (IF) staining of 
MCF-7 cells, the antibodies used were rabbit anti-IL-10Rα (Santa Cruz Biotechnology, Santa 
Cruz, CA, sc-984, 1:100), followed by goat anti-rabbit-TRITC (Southern Biotech, Birmingham, 
AL, #4010-03, 1:150).  The IF antibodies were diluted with antibody dilution buffer (1% BSA, 
0.5% Tween-20, 1X PBS) by the dilution factor indicated by the manufacturer.  HFF-1 cells 
were analyzed for HCMV infection by immunofluorescence staining using mouse anti-US27 and 
anti-US27 rabbit antiserum kindly provided by Dr. Barry Margulies (Towson University, MD, 
1:100), goat anti-cmvUS28 (Santa Cruz Biotechnology, sc-28042, 1:50), or mouse anti-cmvIE1 
(Millipore, MAB810, 1:100).  These anti-virus antibodies were followed by the secondary 
antibodies goat anti-mouse-FITC (Santa Cruz Biotechnology, sc-2010, 1:100), goat anti-rabbit-
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FITC (Santa Cruz Biotechnology, sc-2012, 1:100), donkey anti-goat-FITC (Santa Cruz 
Biotechnology, sc-2024, 1:100) and goat anti-rabbit-TRITC (Southern Biotech, #4010-03, 1:150) 
in antibody dilution buffer.   
Virus Infection and Propagation.  A 95% confluent monolayer of HFF-1 cells in a T75 flask 
was inoculated with HCMV strain AD-169 (ATCC) according to the suppler’s instructions.  The 
T75 flask was observed until >90% cytopathic effects (CPE) were obtained, requiring 
approximately 15 days.  Viral propagation was originally maintained in a cell-associated manner, 
by harvesting infected HFF-1 cells with trypsin and dispensing 2x105 cells onto a new 95% 
confluent monolayer of uninfected HFF-1 cells in a T75 flask.  Viral stocks were obtained from 
the remaining infected HFF-1 cells by pelleting and resuspending the cells in 1 mL PBS.  
Infected cells were disrupted by sonification with a Branson Sonifier 250 (Cycle Duty 2, Output 
2) for 30 seconds.  The clarified sonicate was frozen at -80°C for future use.  After optimizing 
the viral propagation procedure, viral propagation was achieved by inoculating a T75 flask 
containing a 95% confluent monolayer of uninfected HFF-1 cells with 1mL supernatant from a 
T75 flask of HFF-1 cells infected with HCMV at >90% CPE.  This optimized procedure was 
repeated once weekly when >90% CPE was observed. 
Flow Cytometry.  MCF7 cells were grown to 80% confluency and then serum starved for 24 
hours prior to harvesting.  Cells were scraped into serum-free media, pelleted and resuspended in 
fluorescence activated cell sorter (FACS) buffer (PBS pH 7.4, 0.5% BSA, 0.02% sodium azide).  
Samples of 1x105 cells each were stained with 5 µL phycoerythrin-conjugated polyclonal anti-
human IL-10R antibodies in a total volume of 100 µL FACS buffer on ice in the dark for 60 
minutes.  The cells were washed three times and fixed in 100 µL cold FACS buffer plus 100 µL 
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PBS containing 2% paraformaldehyde.  Each sample was analyzed using a Becton-Dickinson 
FACSCalibur Flow Cytometer and Cell Quest Pro software. 
Immunofluorescence.  MCF-7 cells were seeded on FBS-treated glass coverslips in 6-well 
plates at 2x105 cells per well.  The cells were allowed to adhere and grow for 48 hours to achieve 
70-80% confluency. The media was removed and replaced with serum free media overnight.  
The cells were washed with PBS and fixed in 4% paraformaldehyde, then permeabilized with 
0.2% Triton-X-100 in phosphate-buffered saline (PBS) for 15 minutes, followed by an ice cold 
acetone:methanol solution for 30 minutes at room temperature.  MCF-7 cells were blocked with 
10% FBS in PBS at 37°C for 1 hour, then stained with primary antibody for 1 hour, followed by 
secondary antibody for 30 minutes each at 37°C in the dark.  Where indicated, HFF-1 cells were 
seeded on FBS-treated glass coverslips in 6-well plates at 7x104 cells per well.  The cells were 
allowed to adhere and grow for 96 hours to achieve >80% confluency, then infected using 5x104 
HCMV-infected cells.  At 72 hours post-infection the cells were fixed, permeabilized and 
blocked as described above.  HFF-1 cells with or without HCMV infection were blocked with 
10% FBS in PBS at 37°C for 1 hour, then stained for viral gene products with primary antibody 
for 1 hour, followed by secondary antibody for 30 minutes each at 37°C in the dark.  All slides 
were mounted in ProLong Gold anti-fade reagent with DAPI (Invitrogen, Grand Island, NY) and 
analyzed with an inverted AxioObserver fluorescence microscope (Carl Zeiss Microscopy, 
Oberkochen, Germany) mounted with a digital camera.  Digital images were taken with 
AxioVision Rel 4.8 software (Carl Zeiss Microscopy). 
RNA Preparation and Quantitative Real-Time Polymerase Chain Reactions (qRT-PCR).  
Two T75 flasks at 90% confluence containing 3x106 MCF-7 cells each were treated with 100 
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ng/mL purified recombinant cmvIL-10 (R&D Systems) for 24 hours, or an equal amount of PBS 
as a vehicle control (Figure 7).  The RNA was harvested from cells using the RNeasy Midi Kit 
(Qiagen, Germantown, MD) according to manufacturer’s instructions and treated with RNase-
Free DNase (Qiagen) to further remove any contaminating DNA from the samples.  RNA was 
analyzed using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE) to 
measure concentration and purity.  Using the RT2 First Strand Kit (SABiosciences, Valencia, 
CA), cDNA was synthesized via reverse transcription from 1 µg of purified RNA.  Polymerase 
chain reaction (PCR) component mixes were prepared using RT2 SYBR Green Mastermix 
(SABiosciences) according to manufacturer’s instructions, and 25 µL mix was dispensed into 
each well of the RT2 Profiler PCR Human Tumor Metastasis Array (SABiosciences, PAHS-
028ZD-2) (Figure 7).  The plates were run using the CFX96 Real-Time System cycler (BioRad, 
Hercules, CA), adhering to a two-step cycling program.  One 10-minute cycle at 95°C was 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  MyiQ software (BioRad) 
was used to analyze gene expression.   
Enzyme-Linked Immunosorbent Assay (ELISA).  Clear bottom 96-well plates were seeded 
with 5x103 MCF-7 cells per well and treated with 0, 1, 10, or 100 ng/mL purified recombinant 
cmvIL-10 (R&D Systems) in triplicate.  Cell supernatants were harvested and frozen at -20°C 
after 24, 48, 72, 96, 120, or 144 hours for subsequent analysis.  Cell lysates were also collected 
from these plates by adding 100µL cell lysis buffer (150mM NaCl, 20 mM HEPES, 0.5% Triton 
X-100, 1mM NaOV4, 1mM EDTA, 0.1% NaN3) with 1:100 fresh protease inhibitor 
(Calbiochem, La Jolla, CA) onto the cells and administering a freeze-thaw cycle.  Where 
indicated, MCF-7 cells were also treated with conditioned medium from HFF-1 cells infected 
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Figure 7. A schematic illustration of the qRT-PCR method.  To compare gene 
expression related to metastasis of breast cancer cells in the presence or absence of purified 
recombinant cmvIL-10, RNA was isolated from cells, cDNA was synthesized, and plates were 
loaded with samples for PCR array. 
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with HCMV AD-169.  MCF-7 cells were seeded as described above and grown in 1:1 complete 
media and conditioned medium from HFF-1 cells 5 days post infection exhibiting 100% CPE.  
Supernatant and cell lysate samples were collected and frozen as discussed above.  Samples were 
then measured for MMP 2, MMP 3, MMP 7, MMP 9, MMP 10, human IL10, TGFβ, TNFα, IL-
6, IL-1β protein levels by ELISA, performed according to manufacturer’s instructions (R&D 
Systems Duo Sets).  Samples of supernatant from HFF-1 cells in the presence or absence of 
HCMV infection were also evaluated by ELISA for the aforementioned proteins.  Protein 
concentrations in each of the cell supernatant or cell lysate samples were determined by 
interpolation from a standard curve with an R2 value greater than 0.99 using the Opsys MR plate 
reader and Revelation Quicklink 4.24 software (Dynex Technologies, Chantilly, VA). 
Migration Assays.  Cells were cultivated in serum free media in the presence or absence of 100 
ng/mL cmvIL-10 for 24 hours.  For migration assays, well filters (ThinCerts, 24 well, 8 µm pore, 
E & K Scientific, Santa Clara, CA) were loaded into 24-well plates using sterile tweezers to 
create Boyden Chambers (Figure 8).  Cells were harvested via scraping, washed, and 
resuspended in fresh serum free media.  A total of 2x105 cells in a volume of 100 µL in the 
presence or absence of 100 ng/mL cmvIL-10 were dispensed into each upper chamber.  Lower 
chambers were loaded with 600 µL media with 1% FBS and 100 ng/mL cmvIL-10 was added to 
media in the lower chambers of wells where indicated (Figure 8).  The plates were incubated at 
37°C for 4 hours, and then cells were harvested from the lower chamber by dipping the filter in 
the lower chamber media 10 times and rinsing the bottom of the filter twice using lower chamber 
media.  Media and cells that were adhered to the outside of the filter were removed by pipet, and 
then the lower chamber well media was collected and placed into a microfuge tube and 
centrifuged at 1000 rpm for 5 minutes.  All but 100 µL of media was removed from the 
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Figure 8. Boyden chamber assay to investigate cell motility.  The upper chambers 
contain breast cancer cells suspended in serum free media in the presence or absence of cmvIL-
10.  The lower chambers contain 1% FBS in media in the presence or absence of cmvIL-10.  
Migration of breast cancer cells from the upper chamber to the lower chamber was quantified by 
harvesting cells from the lower chamber after 4 hours of incubation and measuring relative light 
units with the Cell Titre Glo Assay. 
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microfuge tube, in which the cell pellets were resuspended.  The samples were placed into a 
white clear bottom assay plate and cell quantity was measured using the Cell Titre Glo Assay 
according to the manufacturer’s instructions.  The plates were read with a GloMax luminometer 
(Promega) using GlowMax software to measure relative light units. 
 
Bishop,	  Robin	  
26	  
	  
Results 
I.  Human IL-10 Receptor Is Present on the Surface of Breast Cancer Cells 
This research project explores the alteration of the cellular activities of human breast cancer 
cells when placed in the presence of a viral cytokine, cmvIL-10.  To determine whether cmvIL-
10 has a role in modulating breast cancer metastasis, we examined the availability of the human 
IL-10 cellular receptor on the surface of MCF-7 breast cancer cells.  Flow cytometry was 
performed on MCF-7 cells that had been cultivated in the absence of serum and then stained with 
fluorochrome-conjugated IL-10R α and β antibodies.  Figure 9 illustrates the presence of both 
chains of the hIL-10 receptor on the surface of the cancer cells, as evidenced by right shifted 
fluorescence compared to isotype control antibodies. 
In addition to flow cytometry, we employed immunofluorescence microscopy to demonstrate 
the availability of hIL-10R for binding with cmvIL-10 on the surface of MCF-7 breast cancer 
cells and to visualize IL-10R distribution throughout the cell.  Cells were grown on glass cover 
slips, fixed, permeabilized and labeled with an antibody specific for hIL-10Rα.  The image in 
Figure 10 illustrates hIL-10Rα is distributed in a discrete punctate fashion throughout the MCF-7 
cells.  Cell nuclei are labeled with DAPI in blue and the cytokine receptor hIL-10Rα is labeled in 
red.  The receptor is present inside and on the surface of the breast cancer cells, including 
extending along cellular appendages.  The microscopy results, in conjunction with the flow 
cytometry results, demonstrate the abundant availability of human IL-10 receptor on the surface 
of MCF-7 breast cancer cells. 
II.  CmvIL-10 Changes the Transcriptional Expression of Tumor Metastasis-Related Genes 
The complete alteration of cellular activity due to the binding and signaling of cmvIL-10 is 
not fully defined.  Considering the connection between HCMV and cancer progression, we 
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Figure 9. Flow cytometry shows the Human IL-10 Receptor is present on the surface of 
MCF-7 breast cancer cells.  Flow cytometry was performed on serum-starved MCF-7 cells in 
order to confirm the expression of hIL-10R on the surface of the cells.  In the upper panel A, the 
blue line in the histogram denotes the goat IgG isotype, and the grey shaded area shifted to the 
right illustrates the presence of the fluorochrome-conjugated goat anti-IL-10Rα antibody 
detected on the surface of the cells.  In the lower panel B, the blue line in the histogram denotes 
the mouse IgG1 isotype, and the grey area shifted to the right illustrates the presence of the 
fluorochrome-conjugated goat anti-IL-10Rβ antibody detected on the surface of the cells. 
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Figure 10. Immunofluorescence microscopy reveals the Human IL-10α Receptor on 
MCF-7 breast cancer cells.  Immunofluorescent staining with rabbit anti-hIL-10Rα followed by 
goat anti-rabbit-TRITC was performed to visualize the cytokine receptor.  In the image of the 
left, the cell nuclei are labeled blue with DAPI and the human IL-10 receptor is shown in red.  
The image on the right is stained with DAPI and the secondary antibody goat anti-rabbit-TRITC 
as a control. 
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investigated the impact of purified, recombinant cmvIL-10 on transcription of genes associated 
with tumor metastasis in breast cancer cells.  We conducted gene expression analysis using 
Human Tumor Metastasis RT2 Profiler PCR Arrays (SA Biosciences, Frederick, Maryland), 
which contain primers for 84 genes associated with human tumor metastasis (Table 2 in 
Appendix).  First, highly purified RNA was isolated from MCF-7 breast cancer cells that were 
cultured in the presence or absence of cmvIL-10, cDNA was synthesized from the prepared RNA 
via reverse transcription, and the samples were applied to the microarrays.  The microarray plates 
were run using a BioRad CFX96 Real-Time PCR machine and a change in gene expression was 
determined by comparing the amount of transcription of the genes of interest in cells treated with 
cmvIL-10 compared to the amount of transcription of the genes of interest in cells not treated 
with cmvIL-10.  Figure 11 summarizes the results of 3 experiments and shows that treatment 
with cmvIL-10 changes gene expression of MCF-7 breast cancer cells.  A fold change of more 
than one is interpreted as an up-regulation of the gene of interest, and a fold change of less than 
one is interpreted as a down-regulation of the gene of interest.  Although differences between the 
means were not statistically significant (p > 0.05, student’s t-test), Figure 11 indicates, in green, 
five genes which were up-regulated more than 2-fold due to treatment with cmvIL-10 for both 24 
and 48 hours, including FAT1, ITGB3, MCAM, SET, and SMAD2.  Two additional genes 
indicated in green, SSTR2, RB1, were also up-regulated more than 2-fold by cmvIL-10 after 48 
hours of treatment.  Moreover, Figure 11 indicates 4 other genes, shown in yellow, were up-
regulated after both 24 hours and 48 hours treatment with cmvIL-10 more than 1.5-fold, DENR, 
EPHB2, PNN, RPSA.  These results illustrate a trend of enduring up-regulation due to treatment 
with cmvIL-10 for the genes mentioned.  Furthermore, 6 genes, shown in yellow, were up- 
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Gene Gene  Description 24  Hours 48  Hours
FGFR4 Fibroblast  growth  factor  receptor  4 0.533 0.677
CST7 Cystatin  F  (leukocystatin) 0.573 0.753
RB1 Retinoblastoma  1 0.593 2.413
IL1B Interleukin  1,  beta 0.637 1.137
FN1 Fibronectin  1 0.643 0.983
NF2 Neurofibromin  2  (merlin) 0.647 0.887
SYK Spleen  tyrosine  kinase 0.647 0.847
CHD4 Chromodomain  helicase  DNA  binding  protein  4 0.650 0.847
MYCL1 V-­‐‑myc  myelocytomatosis  viral  oncogene  homolog  1 0.663 1.287
EWSR1 Ewing  sarcoma  breakpoint  region  1 0.683 0.813
MDM2 Mdm2  p53  binding  protein  homolog  (mouse) 0.683 0.747
SRC V-­‐‑src  sarcoma  viral  oncogene  homolog 0.687 0.967
MTSS1 Metastasis  suppressor  1 0.690 1.030
CD82 CD82  molecule 0.700 1.077
CXCL12 Chemokine  (C-­‐‑X-­‐‑C  motif)  ligand  12 0.710 0.890
APC Adenomatous  polyposis  coli 0.730 1.267
FXYD5 FXYD  domain  containing  ion  transport  regulator  5 0.740 1.043
HTATIP2 HIV-­‐‑1  Tat  interactive  protein  2,  30kDa 0.757 0.873
NR4A3 Nuclear  receptor  subfamily  4,  group  A,  member  3 0.757 0.953
MGAT5 Mannosyl  glycoprotein  acetyl-­‐‑glucosaminyltransferase 0.763 0.920
CD44 CD44  molecule  (Indian  blood  group) 0.767 0.917
GNRH1 Gonadotropin-­‐‑releasing  hormone  1 0.767 0.870
MTA1 Metastasis  associated  1 0.810 1.040
VEGFA Vascular  endothelial  growth  factor  A 0.863 1.123
CTBP1 C-­‐‑terminal  binding  protein  1 0.873 1.323
KRAS V-­‐‑Ki-­‐‑ras2  Kirsten  rat  sarcoma  viral  oncogene  homolog 0.917 1.067
MET Met  proto-­‐‑oncogene  (hepatocyte  GF  receptor) 0.923 1.153
KISS1 KiSS-­‐‑1  metastasis-­‐‑suppressor 0.940 1.287
SMAD4 SMAD  family  member  4 0.940 0.837
IL18 Interleukin  18  (interferon-­‐‑gamma-­‐‑inducing  factor) 0.947 1.033
MMP11 Matrix  metallopeptidase  11  (stromelysin  3) 0.960 1.007
TGFB1 Transforming  growth  factor,  beta  1 0.973 1.467
TNFSF10 Tumor  necrosis  factor  (ligand)  superfamily 0.977 1.133
TP53 Tumor  protein  p53 0.977 1.427
METAP2 Methionyl  aminopeptidase  2 0.993 0.933
ETV4 Ets  variant  4 1.057 1.293
TIMP2 TIMP  metallopeptidase  inhibitor  2 1.060 1.267
BRMS1 Breast  cancer  metastasis  suppressor  1 1.067 1.490
NME1 Non-­‐‑metastatic  cells  1,  protein  (NM23A) 1.070 1.127
TCF20 Transcription  factor  20  (AR1) 1.090 1.430
MMP10 Matrix  metallopeptidase  10  (stromelysin  2) 1.093 1.230
MMP9 Matrix  metallopeptidase  9  (gelatinase  B) 1.103 1.187
CTNNA1 Catenin  (cadherin-­‐‑associated  protein),  alpha  1 1.117 1.403
NME4 Non-­‐‑metastatic  cells  4 1.137 1.263
CXCR4 Chemokine  (C-­‐‑X-­‐‑C  motif)  receptor  4 1.153 1.520
FLT4 Fms-­‐‑related  tyrosine  kinase  4 1.153 1.313
ITGA7 Integrin,  alpha  7 1.187 1.050
HPSE Heparanase 1.203 1.063
CCL7 Chemokine  (C-­‐‑C  motif)  ligand  7 1.217 1.077
CDH6 Cadherin  6,  type  2,  K-­‐‑cadherin  (fetal  kidney) 1.217 1.077
CDKN2A Cyclin-­‐‑dependent  kinase  inhibitor  2A 1.217 1.077
CTSL1 Cathepsin  L1 1.217 1.077
CXCR2 Chemokine  (C-­‐‑X-­‐‑C  motif)  receptor  2 1.217 1.077
HGF Hepatocyte  growth  factor  (hepapoietin  A) 1.217 1.077
IGF1 Insulin-­‐‑like  growth  factor  1  (somatomedin  C) 1.217 1.077
KISS1R KISS1  receptor 1.217 1.700
MMP13 Matrix  metallopeptidase  13  (collagenase  3) 1.217 1.077
MMP3 Matrix  metallopeptidase  3  (stromelysin  1) 1.217 1.077
MMP7 Matrix  metallopeptidase  7  (matrilysin,  uterine) 1.217 1.077
RORB RAR-­‐‑related  orphan  receptor  B 1.217 1.077
TIMP3 TIMP  metallopeptidase  inhibitor  3 1.217 1.077
TIMP4 TIMP  metallopeptidase  inhibitor  4 1.217 1.077
TRPM1 Transient  receptor  potential  cation  channel 1.217 1.077
TSHR Thyroid  stimulating  hormone  receptor 1.217 1.077
COL4A2 Collagen,  type  IV,  alpha  2 1.250 0.993
NME2 Non-­‐‑metastatic  cells  2,  protein  (NM23B) 1.250 1.160
HRAS V-­‐‑Ha-­‐‑ras  Harvey  rat  sarcoma  viral  oncogene  homolog 1.257 1.390
SSTR2 Somatostatin  receptor  2 1.260 2.373
CDH1 Cadherin  1,  type  1,  E-­‐‑cadherin  (epithelial) 1.277 1.407
MMP2 Matrix  metallopeptidase  2  (gelatinase  A) 1.283 1.077
CTSK Cathepsin  K 1.323 1.547
CDH11 Cadherin  11,  type  2,  OB-­‐‑cadherin  (osteoblast) 1.343 1.310
MYC V-­‐‑myc  myelocytomatosis  viral  oncogene  homolog 1.397 1.870
PTEN Phosphatase  and  tensin  homolog 1.433 1.533
PLAUR Plasminogen  activator,  urokinase  receptor 1.440 1.723
EPHB2 EPH  receptor  B2 1.510 1.803
PNN Pinin,  desmosome  associated  protein 1.783 1.820
RPSA Ribosomal  protein  SA 1.827 1.747
DENR Density-­‐‑regulated  protein 1.840 1.710
FAT1 FAT  tumor  suppressor  homolog  1  (Drosophila) 2.213 2.640
ITGB3 Integrin,  beta  3  (platelet  glycoprotein  IIIa) 2.287 4.853
SMAD2 SMAD  family  member  2 2.440 2.573
SET SET  nuclear  oncogene 2.483 2.307
MCAM Melanoma  cell  adhesion  molecule 3.243 3.193  
  > 2-fold Down-Regulation         No Significant Change        1.5 – 2-fold Up-Regulation 
   1.5 – 2-fold Down-Regulation               > 2-fold Up-Regulation 
 
Figure 11. Fold change in tumor metastasis-related gene expression after treatment 
with cmvIL-10 for 24 and 48 hours.  MCF-7 breast cancer cells in the presence or absence of 
cmvIL-10 for 24 and 48 hours were analyzed for expression of genes related to tumor metastasis 
by qRT-PCR arrays.  The fold change represents the ratio between the gene expression in the 
cmvIL-10 treated cells and the untreated control cells, averaged from 3 separate experiments. 
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regulated more than 1.5 fold after a full 48 hours treatment with cmvIL-10, including CTSK, 
CXCR4, KISS1R, MYC, PLAUR, and PTEN. 
Treatment with cmvIL-10 also down-regulated MCF-7 gene expression, but only modestly, 
as down-regulation was observed only after 24 hours of treatment, and no genes were down-
regulated more than 2-fold.  A fold change below 0.66 represents a greater than 1.5-fold down-
regulation in gene expression.  Eight genes, shown in orange in Figure 11, were down-regulated 
between 1.5- and 2-fold due to treatment with cmvIL-10 for 24 hours, including CHD4, CST7, 
GFR4, IL1B, NF2, RB1, RN1, and SKY.  Noteworthy is RB1, which is the only gene to have 
been distinctly down-regulated at 24 hours of treatment with cmvIL-10 and then significantly up-
regulated after 48 hours of treatment with cmvIL-10. 
To further analyze qRT-PCR results and discern a more clear depiction of the role of cmvIL-
10 in gene expression alteration, we sorted the genes into functional groups and removed 
outliers, which are defined as fold changes more than 3 times different than the average of the 
other two fold changes of the same treatment condition.  Results from genes associated with cell 
adhesion were grouped together.  Cell adhesion is important for tissue integrity and stability.  
Cancer cells that lose cell adhesion characteristics may be more likely to undergo invasion and 
develop a metastatic tumor in another part of the body.  Analysis of the qRT-PCR results with a 
focus on genes that encode for gene proteins related to cell adhesion reveals that cmvIL-10 may 
promote a reduction in cell adhesion (Figure 12).  MCAM, or melanoma cell adhesion molecule, 
also known as CD146 and MUC18, is a gene associated with cell migration and angiogenesis.  
MCAM was up-regulated nearly 8-fold after treatment with cmvIL-10 at both 24 and 48 hour 
time points.  This calculation is representative of two experiments with similar results 
demonstrating the significant up-regulation of MCAM due to treatment with cmvIL-10 for 24  
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Figure 12. Depiction of the fold change in adhesion-associated gene expression after 
treatment with cmvIL-10.  MCF-7 breast cancer cells in the presence or absence of cmvIL-10 
for 24 hours were analyzed for expression of genes related to cell adhesion by qRT-PCR array.  
The fold change represents the ratio between the gene expression in the treated cells and the 
control cells.  MCAM and FXYD5 are correlated with increased invasion, while SYK, APC, and 
CDH1 suppress invasion.  Overall, the modulation of adhesion-associated gene expression by 
cmvIL-10 demonstrates a shift toward a transcript profile favoring more metastasis.  Error bars 
represent the range of fold-change values. 
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hours.  Additionally, treatment with cmvIL-10 up-regulated FXYD5, or FXYD domain 
containing ion transport regulator 5, also known as dysadherin, a gene involved in the reduction 
of cell adhesion.  These two genes exhibited an up-regulation in expression due to treatment with 
cmvIL-10, which may result in less cell adhesion and lead to a more invasive phenotype. 
Treatment with cmvIL-10 also down-regulated genes associated with cell adhesion.  Figure 
12 depicts the down-regulation of APC, CDH1, and SYK, cell adhesion genes which are 
associated with tumor suppression.  Tumor suppressor genes are involved in repressing the cell 
cycle and promoting apoptosis.  A loss of function of tumor suppressor genes may lead to 
unregulated cell growth and increased metastasis due to amplified cell proliferation, increased 
angiogenesis, elevated cell detachment and more robust migration.  We show that cmvIL-10 
alters the gene expression profile of genes related to cell adhesion, manipulating cells to produce 
less tumor suppressor gene transcripts, which may cause a phenotypic change favoring 
metastasis. 
Another group of genes analyzed were the genes encoding for MMPs.  MMPs degrade the 
extracellular matrix and permit tumor cells access to the vascular and lymphatic systems, 
allowing cancer cells to disseminate.  Figure 13 depicts the comparison of gene expression of 
cells treated with cmvIL-10 for 24 hours and untreated control cells.  Fold changes were 
calculated by removing outliers and taking the average of two similar ratios.  All MMPs genes 
present on the array were up-regulated in MCF-7 cells exposed to cmvIL-10 for 24 hours.  Gene 
expression of MMP2, MMP3, MMP 11, MMP13 was up-regulated about 1.4-fold and MMP7 
was up-regulated 1.6-fold.  MMP9 and MMP10 were up-regulated the most due to cmvIL-10 
treatment, 2.4-fold and 4.8-fold, respectively.  There was no remarkable change in TIMP gene 
expression to counteract the increase in MMP gene expression, with TIMP2, TIMP3, and TIMP4  
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Figure 13. Depiction of the fold change in MMP gene expression after treatment with 
cmvIL-10.  MCF-7 breast cancer cells in the presence or absence of cmvIL-10 for 24 hours were 
analyzed for expression of genes encoding for MMPs by qRT-PCR.  The fold change represents 
the ratio between the gene expression in the treated cells and the control cells.  All MMPs were 
up-regulated due to treatment with cmvIL-10.  MMP9 was up-regulated 2.4-fold and MMP10 
was up-regulated 4.6-fold.  This shift in gene expression may cause cells to secrete more MMPs, 
further degrading the extracellular matrix and permitting dissemination.  Error bars represent the 
range of fold-change values. 
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all exhibiting average fold-changes between 1 and 1.2.  These results indicate that cmvIL-10 
increases the transcription of genes encoding for MMPs, which may elevate secretion of MMP 
protein levels and promote metastasis. 
III.  Examination of the Secretome of Breast Cancer Cells Treated with CmvIL-10 
To investigate if the changes in gene expression observed by qRT-PCR correlate with an 
increase in protein levels, the presence of MMPs in supernatants from MCF-7 cells treated with 
purified recombinant cmvIL-10 was examined.  Supernatants were collected and the levels of 
MMP2, MMP3, MMP7, MMP9, and MMP10 were determined by sandwich ELISA.  While total 
secreted MMP levels were expected to be higher in breast cancer cells due to the observed 
increase in MMP gene expression, no MMP protein was detected in cell supernatants following 
cmvIL-10 treatment.  ELISAs were also conducted measuring the levels of TIMP1 in MCF-7 
cell supernatant to determine if TIMP1 was present and might be interfering with the detection of 
MMP proteins.  Abundant TIMP1 was detected, unlike MMPs, yet no change in TIMP1 levels 
was observed due to the treatment of cmvIL-10.  Figure 14 illustrates the presence of TIMP1 
proteins in MCF-7 cell supernatant, and a lack in change of TIMP1 levels due to treatment with 
cmvIL-10.  These data support the qRT-PCR data showing a minimal change in TIMP gene 
expression due to treatment with cmvIL-10. 
While an increase in MMP gene expression was observed by qRT-PCR, it is possible that 
MMP protein levels are elevated in breast cancer cells in the presence of cmvIL-10, but the 
proteins are not being secreted by the cells.  MMPs are often cell-associated, and these 
membrane-type (MT)-MMPs would not be secreted by the cell into the supernatant, but remain 
tethered to the cell membrane.  To investigate if the change in MMP gene expression could be  
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Figure 14. Extracellular TIMP1 concentration is not affected by cmvIL-10.  MCF-7 
breast cancer cells in the presence or absence of cmvIL-10 were analyzed for TIMP1 protein 
levels by ELISA.  The concentration of TIMP1 was not altered due to treatment with the viral 
cytokine cmvIL-10.  These results support the qRT-PCR results demonstrating no change in gene 
expression was observed for the TIMP genes investigated.  Error bars represent the range of 
concentrations measured for each condition. 
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Figure 15. Extracellular TGF-β concentration is decreased by cmvIL-10.  MCF-7 breast 
cancer cells in the presence or absence of cmvIL-10 were analyzed for TGF-β protein levels by 
ELISA.  The concentration of TGF-β was decreased by the viral cytokine cmvIL-10, most 
substantially after 72 hours of treatment.  Error bars represent the range of concentrations 
measured for each condition.
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translated into an increase in MT-MMPs, cell lystates were collected and screened for MMP9 
and MMP10.  However, no MMP9 or MMP10 were detected by ELISA from the cell lysate  
samples.  Future investigations of MMP2, MMP3 and MMP7 may uncover MMP protein in cell 
lysates from MCF-7 cells treated with cmvIL-10. 
Furthermore, the secretome of MCF-7 breast cancer cells treated with cmvIL-10 was also 
examined for other proteins associated with cancer progression by ELISA, including TGF-β, 
TNF-α and interleukins IL-1β and IL-6.  Figure 15 shows that TGF-β protein levels were found 
to decrease due to treatment with cmvIL-10, despite only minimal alterations at the 
geneexpression level.  While TGF-β is often largely considered a mitogenic protein, it also 
contributes to facilitating apoptosis.  Therefore, cmvIL-10 could promote tumor progression by 
decreasing TGF-β, which may lead to less apoptosis and increased viability of breast cancer 
cells.  Lastly, no TNF-α, IL-1β, or IL-6 proteins were detected in cell supernatants. 
IV.  CmvIL-10 Promotes Migration 
Cellular activity depends on an enormous variety of factors.  One cell activity that is vital for 
metastasis is the ability of cells to be motile.  Using Boyden chambers, we investigated the 
migration capability of breast cancer cells toward fetal bovine serum, which contains a variety of 
growth factors and chemotactic agents, in the presence or absence of cmvIL-10.  We determined 
the concentration of FBS that provided the most motility from the upper to the lower chamber.  
MCF-7 cells were harvested by scraping an 80% confluent monolayer and 2x105 cells were 
placed in the upper chamber of each well in 100 µL serum free media.  In the lower chamber, 
medium containing varying amounts of FBS was plated.  After 4 hours incubation at 37°C, cells 
were harvested and relative light units were measured using the Cell Titer Glo Assay.  Figure 16 
depicts that MCF-7 cells migrate robustly toward 1% FBS in lower chambers.  To investigate the 
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Figure 16. Breast cancer cells migrate robustly toward 1% FBS.  MCF-7 breast cancer 
cells were placed in the upper portion of the Boyden chamber in serum free media and migrated 
toward media with different concentrations of FBS in the lower chambers.  Error bars represent 
the range of RLUs measured for each condition. N = 3. 
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ability of cmvIL-10 to modulate this migratory action, assays were constructed so that all lower 
chambers had 1% FBS.   
To determine optimal placement of cmvIL-10 in the Boyden chamber, 100 ng/mL cmvIL-10 
was placed in the serum free media upper chamber, in the lower chamber with 1% FBS, in both 
chambers, or in neither.  Figure 17 shows that the most active migration is observed when 
cmvIL-10 is in both the upper and lower chambers.  Fold changes were calculated by comparing 
migration toward serum free media in the lower chamber (blue bars) and migration toward 1% 
FBS in the lower chambers (red bars) with cmvIL-10 in the same location.  While migration with 
cmvIL-10 in both the upper and lower chambers did not have the largest fold change, it was high 
and had the least error.  We decided to pursue this condition in future assays.  Different 
concentrations of cmvIL-10 were explored to investigate which concentration promoted 
migration the most.  Figure 18 illustrates that MCF-7 cells in the presence of 1 ng/mL cmvIL-10 
migrate toward cmvIL-10 and 1% FBS more than any other condition.  These results indicate 
that breast cancer cells in the presence of cmvIL-10 migrate 13-fold more than cells not treated 
with the viral cytokine.  This represents a 138% increase in migration compared to untreated 
breast cancer cells, calculated by determining the percent of the ratio of the average RLUs 
measured from migrated cells treated or untreated with cmvIL-10.  The results demonstrate that 
cmvIL-10 impacts breast cancer cell activity by increasing cell migration, which may contribute 
to breast cancer progression by promoting metastasis in the body.  
V.  Examination of the Secretome of HFF-1 Cells Infected with HCMV 
HCMV infected cells may secrete many factors other than cmvIL-10 that could influence 
tumor progression.  We considered it possible that breast cancer cells, upon exposure to 
supernatants from nearby virus infected cells, may secrete more proteins like MMPs after  
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Figure 17. Breast cancer cells migrate robustly when cmvIL-10 is in both upper and 
lower chambers.  MCF-7 breast cancer cells were placed in the upper portion of the Boyden 
chamber in serum free media and migrated toward media with 1% FBS in the lower chambers 
(shown in red).  Control chambers were established that contained cells in the same conditions 
except they migrated toward serum free media (shown in blue).  100 ng/mL cmvIL-10 was 
dispensed in the upper chamber, lower chamber, both chambers, or neither chamber.  Fold 
changes were calculated by comparing the cell migration toward the media with 1% FBS in the 
lower chambers, and are indicated above each pair of bars in the graph.  Error bars represent the 
range of RLUs measured for each condition. N = 3. 
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Figure 18. Breast cancer cells migrate more actively with 1 ng/mL cmvIL-10.  MCF-7 
breast cancer cells were placed in the upper portion of the Boyden chamber in serum free media 
and different concentrations of cmvIL-10 .  Cells migrated toward media with 1% FBS in the 
lower chambers and the same concentration of cmvIL-10 as the upper chamber (red bars).  Fold 
changes were calculated by comparing migration toward serum free media in the lower chamber 
with cmvIL-10 in the same location (blue bars) as the migration being measured toward 1% FBS 
in the lower chambers (red bars).  Cells migrated most actively in chambers containing 1 ng/mL 
cmvIL-10, exhibiting a fold-change of 13.3, which is 138% more migration than cells not treated 
with cmvIL-10.  Error bars represent the range of RLUs measured for each condition. N = 3. 
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receiving signals from HCMV infected cells.  Additionally, it is possible that cmvIL-10 may 
cooperate with another human or viral protein to induce changes to promote metastasis of breast 
cancer cells.  To explore these possibilities, it was important to first characterize the proteins 
present in the supernatant of HCMV infected cells in order to deduce how HCMV infection 
contributes to tumor progression.  
Since HCMV infection is very selective in cell culture, human foreskin fibroblasts (HFF-1) 
were grown to confluency in a monolayer and subsequently infected with HCMV strain AD-169.  
Cytopathic effects were observed, including enlarged cells, retraction of cytoplasmic extensions, 
and irregular cell margins.  Immunofluorescence was performed to confirm HCMV infection by 
staining for viral proteins IE1, US27, and US28.  Figure 19 depicts images of uninfected HFF-1 
cells on the left and images of HFF-1 cells infected with HCMV on the right.  Cellular nuclei 
were stained with DAPI and can be observed in blue.  The Immediate Early 1 gene product is 
stained in green and is co-localized in the nucleus of infected cells.  The US27 viral gene product 
(green) is depicted in its customary distribution localized primarily on one side of the nucleus of 
infected cells, compared to no US27 protein present on uninfected cells.  US28 protein is shown 
in a red punctate pattern in the HCMV infected cells, compared to a lack of US28 in uninfected 
cells. 
After confirming infection of HFF-1 cells with HCMV, we examined the secretome of 
infected cells.  HFF-1 cells were plated at 5x103 cells per well and grown to 90% confluency.  
Wells were infected with equal amounts of isolated HCMV or PBS vehicle control.  CPE was 
observed to be 10%, 30%, 80% at 24, 48 and 72 hours respectively when supernatants were 
collected and frozen at -20°C.  Supernatants of HFF-1 cells infected or uninfected with HCMV 
were measured for protein levels by ELISA.  MMP3 levels were shown to remain relatively  
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Figure 19. HFF-1 cells were infected with HCMV AD169 and stained for viral proteins 
IE1, US27 and US28.  Immunofluorescence imaging shows cell nuclei stained with DAPI in 
blue.  Uninfected HFF-1 cells are depicted in the left and HFF-1 cells infected with HCMV are 
on the right.  A mouse anti-Immediate Early 1 antibody followed by goat anti-mouse-FITC 
stained the viral gene product IE1 green.  A mouse anti-US27 antibody followed by goat anti-
mouse-FITC stained the viral gene product US27 green also.  A goat anti-US28 antibody 
followed by donkey anti-goat-TRITC stained the viral gene product US28 red. 
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constant over the course of the infection, and were observed at lower levels than uninfected HFF-
1 cells (Figure 20).  The concentration of MMP3 was lower in infected cells than uninfected cells  
at all time points post infection.  The lower levels of MMP3 observed may have been due to the 
mortality of HFF-1 cells due to viral infection.  Notably, the levels of MMP3 cells did not 
diminish over the course of the infection, despite fewer cells viable to secrete MMP3 due to 
mortality from viral infection.  It is possible that more MMP3 per infected cell was being 
secreted compared to uninfected cell.   
MMP10 levels were also measured in supernatant from HFF-1 infected cells compared to 
uninfected cells (Figure 21).  At 24 hours post infection, MMP10 was 2.3-fold higher in HCMV 
infected cells.  MMP10 was elevated at 48 hours as well, and remained at the same level at 72 
hours post infection, while uninfected cell MMP10 levels continued to increase, so that by 72 
hours MMP10 levels were secreted less by HCMV infected cells than uninfected cells.  These 
results demonstrate that HCMV infection increases release of MMP10 from HFF-1 cells 
immediately after infection.  Considering that MMPs liberate growth factors and other MMPs 
from the extracellular matrix, this increase in MMP10 due to viral infection may have grave 
implications if the secretome from HCMV infected cells signal to breast cancer cells.  Finally, no 
MMP2, MMP7 or MMP 9 was detected in supernatant from HFF-1 cells by ELISA.  These 
experiments allow a better characterization of the changes to the secretome due to HCMV 
infection.  These changes may directly impact tumor progression when an infected cell is nearby 
a breast cancer cell.  To explore this impact, we collected supernatant from HFF-1 cells infected 
with HCMV and treated MCF-7 breast cancer cells with the conditioned medium, to determine 
changes in protein levels secreted from the tumor cells.   
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Figure 20. MMP3 concentration secreted from HFF-1 cells infected with HCMV.  
Supernatant from HFF-1 cells infected with HCMV were analyzed for MMP3 protein levels by 
ELISA compared to supernatant uninfected HFF-1 cells.  Error bars represent the range of 
concentrations measured for each condition. N = 3. 
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Figure 21. MMP10 concentration is increased after 24 and 48 hours post HCMV 
infection.  Supernatant from HFF-1 cells infected with HCMV were analyzed for MMP10 
protein levels by ELISA compared to supernatant uninfected HFF-1 cells.  Error bars represent 
the range of concentrations measured for each condition.  N = 3.
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VI.  Examination of the Secretome of MCF-7 Cells Treated with Conditioned Medium 
from HFF-1 Cells Infected with HCMV 
Heterotypic signaling is the communication between dissimilar cell types.  HCMV may alter 
the signaling molecules broadcasted by cells during communication, for example the increase in 
MMP10 levels secreted by HFF-1 cells due to HCMV infection.  Considering the elevated levels 
of MMP transcripts in MCF-7 breast cancer cells due to treatment with cmvIL-10, yet no 
detectable MMP proteins in MCF-7 supernatant, we considered that the lack of secretion of 
MMPs may be due to the absence of a signaling factor from another cell.  To investigate if MCF-
7 cells would secrete more MMPs or other proteins related to cancer metastasis after receiving 
signals from HCMV infected cells, we treated MCF-7 cells with conditioned medium from HFF-
1 cells infected with HCMV strain AD-169 and examined the secretome.  An ELISA measuring 
MMP3 did not detect any MMP3 protein in the MCF-7 secretome after treatment with 
conditioned medium.  Future experiments measuring for other MMPs may reveal that 
conditioned medium from HCMV infected cells unmasks factors in the tumor cell 
microenvironment, permitting MMPs to be secreted and detectable, and further indicating 
HCMV as a promoter of cancer progression. 
We found that MCF-7 human breast cancer cells express the cellular IL-10 receptor, and 
treatment with cmvIL-10 alters expression of cell adhesion molecules and increases MMP gene 
expression.  CmvIL-10 alters cellular activity by promoting cell migration.  While MMP protein 
levels were not detected in the secretome of MCF-7 cells after treatment with cmvIL-10, HCMV 
infection increases MMP10 protein level secretion by HFF-1 cells, which may stimulate nearby 
breast cancer cells to metastasize more readily.
Bishop,	  Robin	  
49	  
	  
Discussion 
The ability of cancer cells to invade other tissues and spread to organs throughout the body is 
detrimental to patient recovery.  Between one-half and two-thirds of American women diagnosed 
with Stage II and III breast cancer will develop at least one secondary tumor within 5 years of 
diagnosis (39).  Breast cancer tumors spread most frequently to the lymph nodes, lungs, liver and 
bones (50).  Current research implicates HCMV as a contributor to some types of cancer 
progression (12, 43).  Neuroblastoma cells infected with HCMV demonstrate down-regulation of 
adhesion molecules and exhibit increased motility (3).  Additionally, HCMV has been detected 
in normal and neoplastic breast epithelium (23).  The consequences of HCMV infection on the 
progression of breast cancer, however, have not been fully established. 
To elucidate this connection, it was vital to examine the various mechanisms HCMV uses to 
manipulate the host cell environment (57).  HCMV actively modulates multiple cell regulatory 
and signaling pathways in healthy, HCMV-seropositive humans (9).  Manipulation of the host 
cell is achieved, in part, by the viral protein cmvIL-10.  CmvIL-10, a powerful viral cytokine 
secreted from infected cells, is a homolog of human IL-10 with greater affinity than the human 
protein for the cellular IL-10 receptor (59).  Research shows that cmvIL-10 effects are largely 
mediated through engagement of the IL-10R and subsequent activation of the Stat 3 pathway, 
which is primarily immunosuppressive (19, 64).  These cellular changes could have vast 
implications in instances where cmvIL-10 is secreted near a breast tumor, as Stat 3 is associated 
with poor prognosis in ovarian cancer and considered a key factor in metastasis formation (79).  
Additionally, elevated levels of MMPs have been associated with poor prognoses in breast 
cancer progression (21).  This thesis project examined cmvIL-10 and its effect on two factors 
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strongly associated with metastatic development, MMP activity and migration, in breast cancer 
progression. 
We demonstrated that MCF-7 breast cancer cells display the human IL-10 receptor.  Flow 
cytometry revealed cells express both Human IL-10Rα and IL-10Rβ on the cell surface (Figure 
9).  Additionally, immunofluorescence with permeablilization allowed visualization of human 
IL-10 receptor in a discrete punctate distribution throughout the cell (Figure 10).  These results 
illustrated that human IL-10 receptor is available for binding on MCF-7 breast cancer cells and 
that, consequently, these cells could be sensitive to cmvIL-10 if present in the tumor 
microenvironment.   
When these cells were treated with cmvIL-10, transcriptional expression of genes related to 
tumor metastasis was altered (Figure 11).  Five genes related to metastasis were up-regulated 
more than 2-fold after both 24 and 48 hours of treatment with cmvIL-10, including FAT1, 
ITGB3, MCAM, SET, and SMAD2.  The FAT1 and ITGB3 gene products are both involved in 
cell communication and migration (4, 52).  MCAM is a multifunctional molecule called 
melanoma cell adhesion molecule, indicated in cell migration, angiogenesis and immune 
response (74).  The SET gene product inhibits acetylation of nucleosomes to inhibit apoptosis 
(36).  The SMAD2 gene product mediates TGF-β and acts as a transcription repressor (44).  
CmvIL-10 treatment consistently alters gene transcription of breast cancer cells over two days by 
distinctly up-regulating genes correlated to tumor progression and metastasis.   
Additionally, treatment of breast cancer cells with cmvIL-10 led to modulations of adhesion-
associated gene expression that involved a shift toward a transcript profile favoring more 
metastasis.  Cell adhesion is important for tissue integrity and stability, and cancer cells that 
express less genes that permit cell adhesion may be more likely to detach from the primary 
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tumor.  Cell adhesion genes FXYD5 and MCAM expression were up-regulated by treatment 
with cmvIL-10 (Figure 12).  High levels of MCAM in human breast cancer cells are associated 
with loss of cell-cell contacts, expression of markers related to a phenotypic epithelial to 
mesenchymal transition, and increased cell motility (27, 76).  FXYD, or domain containing ion 
transport regulator 5, also known as dysadherin, is a gene involved in the reduction of cell 
adhesion via E-cadherin as well as a biomarker for invasion (2).  Also, APC, CDH1 and SYK 
cell-adhesion genes were down-regulated by treatment with cmvIL-10 (Figure 12).  APC, or 
adenomatous polyposis cell, is a tumor suppressor gene indicated in inhibiting tumor 
invasiveness (53).  SYK, or spleen tyrosine kinase, is a tumor suppressor gene that inhibits tumor 
growth, invasion and metastasis in breast cancer cells (67).  Finally, the loss of function of 
CDH1, also known as cadherin 1 and  E-cadherin, may contribute to tumor progression by 
increasing proliferation, invasion and metastasis (38).  Therefore, the modulation of these cell 
adhesion genes demonstrates a shift in gene expression toward less adhesion-related proteins and 
an increased potential for movement away from the primary tumor.  In this way, cmvIL-10 
induces breast cancer cells to transcribe genes that enable detachment from the primary tumor, 
freeing them to begin the invasion process, as well as up-regulating many genes associated with 
migration and metastasis.  Continuing research to determine if these gene expression changes 
translate into altered proteins levels may further elucidate the oncomodulatory activity of cmvIL-
10. 
Matrix metalloproteinases are proteolytic enzymes that degrade the extracellular matrix 
components collagen, fibronectin and laminin (73).  Elevated levels of MMP-13 have been found 
to correlate with poor prognoses in breast cancer patients (77).  In addition, evidence implicates 
the role of MMP-2 and MMP-9 in breast cancer genesis and progression (21, 66).  Breast cancer 
Bishop,	  Robin	  
52	  
	  
cells in the presence of cmvIL-10 demonstrated an up-regulation of genes encoding for MMPs 
(Figure 13), including MMP2, MMP3, MMP7, MMP9, MMP10, MMP11 and MMP13.  An 
increase in degradation of extracellular components due to the presence of cmvIL-10 could 
provide malignant tumor cells access to the vascular and lymphatic systems, leading to further 
dissemination.  The increase of MMP gene transcripts, combined with the modulation of cell 
adhesion and tumor progression genes, indicate cmvIL-10 promotes metastasis-related gene 
expression.  CmvIL-10 alters gene transcription to allow cancer cells to break free of the primary 
tumor, migrate through the extracellular matrix and metastasize in the body.   
Changes in gene transcription often correlate with altered protein levels in cells.  To explore 
the changes in protein levels in breast cancer cells due to treatment with cmvIL-10, the 
secretome of MCF-7 cells was investigated.  Considering the modification of metastasis-related 
gene expression observed, it was expected that cmvIL-10 treatment would cause changes to 
protein levels that would parallel the gene expression data, leading to an increase in MMPs 
secreted by the breast cancer cells.  However, no MMP proteins were detected in cell 
supernatants; ELISAs did not detect MMP2, MMP3, MMP7, MMP9 or MMP10 in the 
supernatant from MCF-7 breast cancer cells.  In interpreting this discrepancy, we considered that 
the MMP proteins might be being synthesized, but that they may be being inhibited by a TIMP.  
The cell supernatant was investigated for TIMP1, an inhibitor of MMPs, and plentiful TIMP1 
was found to be secreted from MCF-7 cells (Figure 14).  Treatment with cmvIL-10 did not, 
however, change the levels of TIMP1.  It is possible that TIMP1, being abundant in the 
secretome, may be interfering with detection of the MMPs by ELISA.  Another possibility is that 
while MMP protein levels are elevated in breast cancer cells in the presence of cmvIL-10, the 
proteins are not being secreted by the cells.  MMPs are often cell associated, and membrane 
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type-MMPs (MT-MMPs) are implicated in breast cancer progression (34, 54).  Future work 
could investigate MT-MMP protein levels in MCF-7 cell lysates to discern the impact of cmvIL-
10 on MT-MMP protein levels in breast cancer cells. 
Supernatants from breast cancer cells in the presence of cmvIL-10 were also explored for 
other factors related to metastasis.  Our work shows that cmvIL-10 decreases levels of TGF-β in 
cell supernatants (Figure 15).  While often considered a mitogenic protein, TGF-β is extremely 
versatile, contributing paradoxically to many cellular functions.  One interesting mechanism of 
TGF-β is its connection with apoptosis.  TGF-β is documented to induce apoptosis through the 
SMAD protein (29).  Our work illustrates how cmvIL-10 can increase SMAD2 gene expression 
and decrease TGF-β protein levels, which may decrease the signaling for apoptosis, resulting in 
increased cancer cell viability.  Future work to quantify SMAD2 protein levels in cell 
supernatant and deducing the cooperation of this protein with the reduced level of TGF- β 
proteins, might demonstrate cmvIL-10 reduces programmed cell death that could ultimately 
contribute to cancer progression. 
Migration is a quantifiable cellular activity.  Migration assays require that breast cancer cells 
migrate through a filter from one chamber to another, where they are harvested and counted.  We 
showed that cmvIL-10 promotes MCF-7 breast cancer cell migration (Figure 18).  Specifically, 
treatment with cmvIL-10 caused MCF-7 breast cancer cells to exhibit 138% more motility than 
cells not treated with the viral cytokine.  The increased migration may be a result of elevated 
gene expression of migration-promoting genes such as those increased by cmvIL-10, FAT1, 
ITGB3, MCAM, and MMPs.  These results showing modified cellular activity demonstrate that 
cmvIL-10, if secreted in the tumor microenvironment by infected cells, may increase breast 
cancer cell survival and invasion, resulting in an increased metastatic risk for cancer patients. 
Bishop,	  Robin	  
54	  
	  
The modulation of gene expression and the robust change in cellular activity due to treatment 
with cmvIL-10 both implicate cmvIL-10 as a tumor-promoting molecule.  One possibility for the 
lack of detection of secreted MMP proteins secreted from breast cancer cells, despite a robust up-
regulation in MMP gene expression, could be due to the absence of a signaling factor from 
another cell.  Heterotypic signaling is the communication between dissimilar cell types.  HCMV 
may alter the signaling molecules broadcasted by cells during communication.  HCMV infected 
cells may secrete multiple factors that work conjointly, which may be necessary to signal MCF-7 
cells to secrete MMPs.  To investigate if MCF-7 cells would secrete more MMPs or other 
proteins related to cancer metastasis after receiving signals from HCMV infected cells, we first 
infected human foreskin fibroblasts with HCMV and characterized the supernatants from HCMV 
infected cells. 
   We found that HCMV actively modulates the secretome of HCMV infected HFF-1 cells.  
Fibroblasts infected with HCMV secreted more MMP10 protein than uninfected HFF-1 cells 
(Figure 21).  An increase in MMP10 in the tumor microenvironment might contribute to the 
degradation of the extracellular matrix surrounding the cancer cells, promoting tumor invasion.  
Additionally, this increase in MMP10 protein level could further transform the tumor 
microenvironment by unmasking other factors in the surrounding extracellular matrix that 
enhance tumor invasion, such as the metastasis-promoting proteins VEGF or TGF-β.  As MMPs 
degrade the extracellular matrix, metastasis-related proteins that are suspended in the meshwork 
in the matrix become liberated and will signal breast cancer cells to proliferate, detach from the 
primary tumor and invade other tissues (22).  In addition to the degradation and remodeling of 
the ECM, MMPs unveil adhesion molecule sites that are usually embedded within the matrix, 
which become available for cell attachment, permitting migration (55).  Furthermore, the altered 
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secretome from HCMV infected cells and the unmasked factors in the tumor microenvironment 
may cooperate with cmvIL-10.  It is possible that a mélange of virally-encoded proteins, 
including cmvIL-10, and the increased availability of secreted cellular proteins such as MMP10 
from HCMV infected cells, as well as the unmasked factors from the remodeled ECM, work 
conjunctively to coordinate a heterotypic signal that induces a metastatic phenotype in the breast 
cancer cell. 
Likely, the effects of HCMV on cancer cell metastasis are additive.  This research 
demonstrates cmvIL-10 plays a stimulatory role in cancer cell migration.  CmvIL-10 also 
contributes to a gene expression profile that favors metastasis. While cmvIL-10 increases MMP 
gene expression in MCF-7 breast cancer cells, additional secreted factors from HCMV infected 
cells may be needed to induce secretion of the MMPs.  Possibly, mRNA transcripts are never 
translated, perhaps due to RNA interference.  Continuing research to further identify proteins in 
the secretome of HCMV infected cells could reveal additional factors that contribute to MMP 
secretion by breast cancer cells.  Finally, future work treating MCF-7 cells with conditioned 
medium from HCMV infected cells may reveal the anticipated elevated MMP protein levels in 
the breast cancer cell secretome, as suggested by qRT-PCR results.   
HCMV orchestrates extensive manipulations of cellular pathways that result in abundant 
micro-effects in the host organism.  While the majority of available research illustrates cmvIL-10 
as a suppressive regulatory cytokine, we show here it exhibits an amplification effect, 
specifically for genes encoding for MMPs and activities like cell migration.  These results 
indicate cmvIL-10 plays an oncomodulatory role through the enhancement of breast tumor 
metastasis.  
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A full 15% of all cancer-related deaths in women are from breast cancer (39).  This alarming 
statistic may be lowered through continued research and discovery.  We show that cmvIL-10 
contributes to cell invasion, thus supporting and expanding on previous studies that implicated 
HCMV as an oncomodulatory virus.  The correlation of HCMV, STAT3, and high MMP levels 
with increased potential for tumor metastasis are supported by this study.  Experiments to 
determine how a latent infection of HCMV affects MMP protein activity would also benefit this 
body of knowledge.  Further research testing the effect of HCMV infection on metastasis in 
animal models will supplement this research project.  In a clinical setting, antiviral therapy may 
be considered in conjunction with chemotherapy efforts for patients who present with highly 
metastatic tumors. 
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Appendix 
Table 2. Human Tumor Metastasis qRT-PCR Gene Array.  A list of the 84 metastasis-
related genes analyzed via qRT-PCR using the RT2 Profiler Human Tumor Metastasis Array. 
Gene Symbol Description Gene Name 
APC Adenomatous polyposis coli BTPS2, DP2, DP2.5, DP3, GS 
BRMS1 Breast cancer metastasis suppressor 1 DKFZp564A063 
CCL7 Chemokine (C-C motif) ligand 7 FIC, MARC, MCP-3, MCP3, MGC138463, MGC138465, NC28, SCYA6, SCYA7 
CD44 CD44 molecule (Indian blood group) CDW44, CSPG8, ECMR-III, HCELL, HUTCH-I, IN, LHR, MC56, MDU2, MDU3, MGC10468, MIC4, Pgp1 
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) Arc-1, CD324, CDHE, ECAD, LCAM, UVO 
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) CAD11, CDHOB, OB, OSF-4 
CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney) CAD6, DKFZp564N1116, FLJ14176, KCAD 
CDKN2A Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 
ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, 
P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, 
TP16 
CHD4 Chromodomain helicase DNA binding protein 4 DKFZp686E06161, Mi-2b, Mi2-BETA 
COL4A2 Collagen, type IV, alpha 2 DKFZp686I14213, FLJ22259 
CST7 Cystatin F (leukocystatin) CMAP 
CTBP1 C-terminal binding protein 1 BARS, MGC104684 
CTNNA1 Catenin (cadherin-associated protein), alpha 1, 102kDa CAP102, FLJ36832, FLJ52416 
CTSK Cathepsin K CTS02, CTSO, CTSO1, CTSO2, MGC23107, PKND, PYCD 
CTSL1 Cathepsin L1 CATL, CTSL, FLJ31037, MEP 
CXCL12 Chemokine (C-X-C motif) ligand 12 IRH, PBSF, SCYB12, SDF1, SDF1A, SDF1B, TLSF, TPAR1 
CXCR4 Chemokine (C-X-C motif) receptor 4 CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R, WHIM 
DENR Density-regulated protein DRP, DRP1, SMAP-3 
EPHB2 EPH receptor B2 CAPB, DRT, EK5, EPHT3, ERK, Hek5, MGC87492, PCBC, Tyro5 
ETV4 Ets variant 4 E1A-F, E1AF, PEA3, PEAS3 
EWSR1 Ewing sarcoma breakpoint region 1 EWS, bK984G1.4 
FAT1 FAT tumor suppressor homolog 1 (Drosophila) CDHF7, CDHR8, FAT, ME5, hFat1 
FGFR4 Fibroblast growth factor receptor 4 CD334, JTK2, MGC20292, TKF 
FLT4 Fms-related tyrosine kinase 4 FLT41, LMPH1A, PCL, VEGFR3 
FN1 Fibronectin 1 
CIG, DKFZp686F10164, DKFZp686H0342, DKFZp686I1370, 
DKFZp686O13149, ED-B, FINC, FN, FNZ, GFND, GFND2, LETS, 
MSF 
FXYD5 FXYD domain containing ion transport regulator 5 DYSAD, IWU1, KCT1, OIT2, PRO6241, RIC 
GNRH1 Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) GNRH, GRH, LHRH, LNRH 
KISS1R KISS1 receptor AXOR12, GPR54, HOT7T175 
HGF Hepatocyte growth factor (hepapoietin A; scatter factor) DFNB39, F-TCF, HGFB, HPTA, SF 
HPSE Heparanase HPA, HPA1, HPR1, HPSE1, HSE1 
HRAS V-Ha-ras Harvey rat sarcoma viral oncogene homolog 
C-BAS, HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV, 
HRAS1, K-RAS, N-RAS, RASH1 
HTATIP2 HIV-1 Tat interactive protein 2, 30kDa CC3, FLJ26963, SDR44U1, TIP30 
IGF1 Insulin-like growth factor 1 (somatomedin C) IGF-I, IGF1A, IGFI 
IL18 Interleukin 18 (interferon-gamma-inducing factor) IGIF, IL-18, IL-1g, IL1F4, MGC12320 
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IL1B Interleukin 1, beta IL-1, IL1-BETA, IL1F2 
CXCR2 Chemokine (C-X-C motif) receptor 2 CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB 
ITGA7 Integrin, alpha 7 FLJ25220 
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) CD61, GP3A, GPIIIa 
CD82 CD82 molecule 4F9, C33, GR15, IA4, KAI1, R2, SAR2, ST6, TSPAN27 
KISS1 KiSS-1 metastasis-suppressor KiSS-1, METASTIN, MGC39258 
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, KI-RAS, 
KRAS1, KRAS2, NS, NS3, RASK2 
RPSA Ribosomal protein SA 37LRP, 67LR, LAMBR, LAMR1, LBP, LBP, p40, LRP, LRP, LR, NEM, 1CHD4, SA, lamR, p40 
MCAM Melanoma cell adhesion molecule CD146, MUC18 
MDM2 Mdm2 p53 binding protein homolog (mouse) HDMX, MGC5370, MGC71221, hdm2 
MET Met proto-oncogene (hepatocyte growth factor receptor) AUTS9, HGFR, RCCP2, c-Met 
METAP2 Methionyl aminopeptidase 2 MAP2, MNPEP, p67, p67eIF2 
MGAT5 Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase GNT-V, GNT-VA 
MMP10 Matrix metallopeptidase 10 (stromelysin 2) SL-2, STMY2 
MMP11 Matrix metallopeptidase 11 (stromelysin 3) SL-3, ST3, STMY3 
MMP13 Matrix metallopeptidase 13 (collagenase 3) CLG3, MANDP1 
MMP2 
Matrix metallopeptidase 2 (gelatinase A, 
72kDa gelatinase, 72kDa type IV 
collagenase) 
CLG4, CLG4A, MMP-II, MONA, TBE-1 
MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 
CHDS6, MGC126102, MGC126103, MGC126104, MMP-3, SL-1, 
STMY, STMY1, STR1 
MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) MMP-7, MPSL1, PUMP-1 
MMP9 
Matrix metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 
CLG4B, GELB, MANDP2, MMP-9 
MTA1 Metastasis associated 1 - 
MTSS1 Metastasis suppressor 1 DKFZp781P2223, FLJ44694, KIAA0429, MIM, MIMA, MIMB 
MYC V-myc myelocytomatosis viral oncogene homolog (avian) MRTL, bHLHe39, c-Myc 
MYCL1 V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian) LMYC, MYCL, bHLHe38 
NF2 Neurofibromin 2 (merlin) ACN, BANF, SCH 
NME1 Non-metastatic cells 1, protein (NM23A) expressed in 
AWD, GAAD, NB, NBS, NDKA, NDPK-A, NDPKA, NM23, NM23-
H1 
NME2 Non-metastatic cells 2, protein (NM23B) expressed in 
MGC111212, MGC2212, NDKB, NDPK-B, NDPKB, NM23-H2, 
NM23B, PUF 
NME4 Non-metastatic cells 4, protein expressed in NDPK-D, NM23H4, nm23-H4 
NR4A3 Nuclear receptor subfamily 4, group A, member 3 CHN, CSMF, MINOR, NOR1, TEC 
PLAUR Plasminogen activator, urokinase receptor CD87, U-PAR, UPAR, URKR 
PNN Pinin, desmosome associated protein DRS, DRSP, SDK3, memA 
PTEN Phosphatase and tensin homolog 10q23del, BZS, DEC, GLM2, MGC11227, MHAM, MMAC1, PTEN1, TEP1 
RB1 Retinoblastoma 1 OSRC, RB, p105-Rb, pRb, pp110 
RORB RAR-related orphan receptor B NR1F2, ROR-BETA, RZR-BETA, RZRB, bA133M9.1 
SET SET nuclear oncogene 2PP2A, I2PP2A, IGAAD, IPP2A2, PHAPII, TAF-I, TAF-IBETA 
SMAD2 SMAD family member 2 JV18, JV18-1, MADH2, MADR2, MGC22139, MGC34440, hMAD-2, hSMAD2 
SMAD4 SMAD family member 4 DPC4, JIP, MADH4 
SRC V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) ASV, SRC1, c-SRC, p60-Src 
SSTR2 Somatostatin receptor 2 - 
SYK Spleen tyrosine kinase DKFZp313N1010, FLJ25043, FLJ37489 
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TCF20 Transcription factor 20 (AR1) AR1, KIAA0292, SPBP 
TGFB1 Transforming growth factor, beta 1 CED, DPD1, LAP, TGFB, TGFbeta 
TIMP2 TIMP metallopeptidase inhibitor 2 CSC-21K 
TIMP3 TIMP metallopeptidase inhibitor 3 HSMRK222, K222, K222TA2, SFD 
TIMP4 TIMP metallopeptidase inhibitor 4 - 
TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 APO2L, Apo-2L, CD253, TL2, TRAIL 
TP53 Tumor protein p53 FLJ92943, LFS1, P53, TRP53 
TRPM1 Transient receptor potential cation channel, subfamily M, member 1 CSNB1C, LTRPC1, MLSN1 
TSHR Thyroid stimulating hormone receptor CHNG1, LGR3, MGC75129, hTSHR-I 
VEGFA Vascular endothelial growth factor A MGC70609, MVCD1, VEGF, VPF 
B2M Beta-2-microglobulin - 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 HGPRT, HPRT 
RPL13A Ribosomal protein L13a L13A, TSTA1 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase G3PD, GAPD, MGC88685 
ACTB Actin, beta PS1TP5BP1 
HGDC Human Genomic DNA Contamination HIGX1A 
RTC Reverse Transcription Control RTC 
RTC Reverse Transcription Control RTC 
RTC Reverse Transcription Control RTC 
PPC Positive PCR Control PPC 
PPC Positive PCR Control PPC 
PPC Positive PCR Control PPC 
*SABiosciences website (http://www.sabiosciences.com/genetable.php?pcatn=PAHS-028A)
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